Results 181 to 190 of about 43,548 (209)
Azacitidine Beyond the Bone Marrow: An Unexpected Journey Into Azacitidine-Induced Arthropathy. [PDF]
CureusBandyopadhyay S +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Hematology, 1979
AbstractAcute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle‐shaped. Electron microscopic appearance of the granules closely resembles that of Auer rods.
J, Groopman, L, Ellman
openaire +2 more sources
AbstractAcute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle‐shaped. Electron microscopic appearance of the granules closely resembles that of Auer rods.
J, Groopman, L, Ellman
openaire +2 more sources
Journal of Pediatric Hematology/Oncology, 1995
Significant advances have occurred in the diagnosis, treatment, and long-term outcome of patients with acute promyelocytic leukemia (APL). The purpose of this review is to describe the molecular genetics of this disease, the use of all-trans retinoic acid (ATRA) in clinical trials of APL, and the clinical and basic research questions for future ...
R S, Lemons +6 more
openaire +2 more sources
Significant advances have occurred in the diagnosis, treatment, and long-term outcome of patients with acute promyelocytic leukemia (APL). The purpose of this review is to describe the molecular genetics of this disease, the use of all-trans retinoic acid (ATRA) in clinical trials of APL, and the clinical and basic research questions for future ...
R S, Lemons +6 more
openaire +2 more sources
New England Journal of Medicine, 1993
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Current Treatment Options in Oncology, 2000
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2014
Acute promyelocytic leukemia (APL) is designated M3 in the French-American-British (FAB) classification. Because of its unique clinical features and unique response to certain differentiation-inducing agents, and because of our advanced understanding of the molecular biology and treatment of this leukemia, APL deserves to be presented and discussed in ...
openaire +1 more source
Acute promyelocytic leukemia (APL) is designated M3 in the French-American-British (FAB) classification. Because of its unique clinical features and unique response to certain differentiation-inducing agents, and because of our advanced understanding of the molecular biology and treatment of this leukemia, APL deserves to be presented and discussed in ...
openaire +1 more source
Acute promyelocytic leukemia in childhood
Current Oncology Reports, 2009Acute promyelocytic leukemia (APL) is a relatively rare form of acute myelogenous leukemia (AML). In the United States, APL in children constitutes only 5% to 10% of AML. Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation ...
John, Gregory, James, Feusner
openaire +2 more sources
[Acute promyelocytic leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013Yuka, Harada, Hironori, Harada
openaire +3 more sources
History of Acute Promyelocytic Leukemia
2017Within a 60-year time span, the most severe acute leukemia—termed acute promyelocytic leukemia (APL) by the Norwegian author Leif Hillestad—was identified, characterized, and cured. The determination of a precise molecular definition of the genetic defect and the emergence of an antidogmatic paradigm have made the history of APL a model for the ...
openaire +2 more sources